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Introduction 
In 2013, researchers at the University of  Nebraska Medical Center 
(UNMC) received funding from the Patient-Centered Outcomes 
Research Institute to establish a protocol that outlines treatment 
options for patients who have stage IV lung cancer. With col-
laborators at 3 other cancer centers, UNMC researchers will 
compare treatment preferences among different patient groups 
when available drugs offer the same survival but different side 
effects. Patient preferences identified in this study can be used to 
inform clinical practice. This paper describes study methods and 
population selection for this patient-centered outcomes research 
(PCOR) on stage IV lung cancer patients and the possible signifi-
cance of  this research for other disease states.
PCOR provides information about the best available evidence to 
help patients and their health care providers make more informed 
decisions. This research is intended to give patients a better un-
derstanding of  the prevention, treatment, and care options availa-
ble and the science that supports those options, and to encourage 
physicians and other clinicians to adopt a more patient-centered 
approach to treatment [1].
PCOR projects require patient voices to be heard in discussions 
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with their physicians in determining the value of  treatment op-
tions. The goal of  a PCOR study is to give patients and their fam-
ily members the information they need to answer patient-focused 
questions such as “Given my personal characteristics, conditions, 
and preferences, what should I expect will happen to me?” or 
“What are my options and what are the benefits and harms of  
those options?”
Conducting a rigorous PCOR study is challenging. In this type 
of  research, the trade-offs between practical issues and internally 
valid designs must be weighed. These trade-offs can be resolved 
by questioning the validity of  the study design or the accuracy 
of  inferences drawn. There is no simple formula for determin-
ing external validity. Researchers must make judgments regarding 
whether the findings would be applicable in other populations. 
These judgments can always be challenged, and researchers may 
have to defend the study’s validity. Concern about the external 
validity of  the results of  PCOR studies is warranted, because such 
studies focus on a very specific patient population’s preferences 
and choices. The research raises the question, “can the results 
of  a PCOR be applied across different populations, in differ-
ent settings, and in other periods of  time?” We propose that the 
outcomes of  our study will be translatable to disease conditions 
other than late stage lung cancer and will provide support for this 
proposition later in this paper.
Background
In the United States, lung cancer is the leading cause of  cancer-
related deaths [2]. In Nebraska, from 2006 to 2010, half  (50%) of  
lung cancer patients were diagnosed at an advanced stage of  dis-
ease. During this same period, 5,979 Nebraskans were diagnosed 
with lung cancer, and 4,537 died from it [3]. Nationally, about 
228,190 new cases of  lung cancer and 159,480 deaths were ex-
pected in 2013. Lung cancer is a major source of  health care costs 
[4, 5]. Stage of  disease at diagnosis strongly affects the prognosis 
for cancer patients. The most recent national data show that the 
5-year survival rate for lung cancers diagnosed at a local stage is 
53.5%, compared to only 3.9% for distant stage cases. Over 50% 
of  stage IV lung cancer patients die within one year of  diagnosis 
[6]
We selected lung cancer for our PCOR focus because of  the num-
ber of  persons who experience this form of  cancer and because 
so many (50%) are diagnosed at late stage, e.g., stage III or IV. 
Further, we decided to limit our study to patients diagnosed with 
non-small cell lung cancer (NSCLC) for two reasons. First, small 
cell lung cancer is often diagnosed only days prior to death, when 
no treatment options are available, and second, NSCLC lung can-
cer is typically treated with a small number of  chemotherapy regi-
mens with outcomes that have not been well studied.
Treatment success for stage IV NSCLC has traditionally been 
measured in terms of  survival. However, it is not known wheth-
er individual patients also see success in terms of  survival. Not 
much is known about patient perspectives on the trade-offs be-
tween possible additional survival and possible side effects related 
to a treatment regimen.
Traditional treatment goals are to prolong survival and control 
disease-related symptoms. There are a limited number of  com-
monly used chemotherapy combinations for the treatment of  
stage IV NSCLC. These drug regimens lead to a similar improve-
ment in survival, but have different toxicity profiles [7]. Thus, tox-
icity profiles are important determinants of  treatment choices and 
treatment success [8].
As with many other medical conditions, patients’ preferences re-
garding adverse effects of  treatment are not systematically con-
sidered when choosing a treatment for stage IV NSCLC. In as-
sessing patient preference, we expect to look at such factors as 
patient perceptions about how much time patients have left to 
live, major changes in life style, impact of  the cancer on fam-
ily and friends, functional status, pain, nausea, and other known 
adverse effects of  chemotherapy. There is no clinical guide for 
patients or physicians on how to integrate patient preferences 
regarding adverse effects into treatment decisions, although it is 
well known that most cancer patients prefer an active or a shared 
role in decision making [9, 10]. Our study will investigate whether 
oncologists, when given patient-specific information, will incor-
porate that information into treatment planning, or, ideally, will 
ask individual patients their preference regarding adverse effects 
of  chemotherapy prior to developing a treatment plan.
We proposed a PCOR study among patients with stage IV NSCLC 
to answer these questions:
(1) In cases of  advanced lung cancer, how do patients define treat-
ment success? (2) Among possible side effects of  treatments with 
about equal prognosis/outcomes, which side effects would pa-
tients most like to avoid? (3) Is a single summary score obtained 
from a list of  patient’s preferred adverse events to predict a real-
life scenario? (4) Will oncologists take patient preferences into 
account when selecting chemotherapy treatment? The purpose 
of  this paper is to describe the study methods and population of  
this PCOR study and to highlight their significance for patient-
centered outcomes research in lung cancer, and for other diseases.
Study Design
For this study of  lung cancer patients and their caregivers, we 
selected a multicenter mixed method design, which includes focus 
groups, and cross-sectional, prospective, and randomized experi-
mental designs to answering the research questions. The multi-
center, mixed method design will allow us to capture the neces-
sary data for all three specific aims and will allow for rapid patient 
recruitment. All participants will be consecutively recruited from 
four cancer treatment centers across Eastern and Central Nebras-
ka and Southern South Dakota.
Data for this clinic-based study will be collected directly, offering 
several advantages over indirect data collection. We expect overall 
higher patient participation with face-to-face data collection, par-
ticularly given that stage IV lung cancer patients are typically age 
70 years and older. In addition, nurse coordinators will be able 
to immediately review patients’ responses, while patients are still 
in the clinic, and obtain missing questionnaire items if  necessary. 
Furthermore, this clinic-based study allows for objective measure-
ment of  clinical variables, such as actual treatment received and 
medical adverse effects experienced. These objective measure-
ments would not be feasible in population-based, phone-based, 
or mail-in designs. With this design, we can also assess changes 
in treatment choices when physicians are provided with patient-
centered adverse effects (PCAE) preferences.
Although focus groups will not examine any specific research 
questions, they play a very important role in this study. Engaging 
patients, their caregivers, and patients’ advocates at early stages of  
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the study can improve study design, execution, and translation, 
and patient satisfaction [9]. We plan to conduct four focus groups 
at two different locations. At each location, we will conduct one 
focus group with patients and their family members and patient 
advocates, and one focus group with cancer center clinicians. Each 
group will include a maximum of  10 participants to promote par-
ticipation by all. A trained focus group facilitator will conduct the 
focus groups; two non-participating note takers and two tape re-
corders will capture participants’ comments. Each focus group 
will last about 90 minutes, and lunch or snacks and beverages will 
be provided to the participants. Focus group recordings and notes 
will be transcribed by two different people and then compared 
for accuracy and consistency. The PI and a student will determine 
thematic content of  the focus groups. To make this study more 
patient-centered, focus group participants will review and com-
ment on all data collection forms to refine the length and time 
required to complete the data collection tools. We will seek input 
from patients and their caregivers on socio-demographic ques-
tions, particularly their preferences regarding answering personal 
or sensitive questions, especially those related to family income. 
More importantly, we will seek suggestions from focus group par-
ticipants on which non-medical adverse effects, such as hair loss, 
brittle nails, increased pain, etc., should be included in this study. 
During focus groups, we will also seek patients’ and caregivers’ 
input on recruitment of  study participants, dissemination of  the 
study findings, and ways to keep patients engaged throughout the 
study. We believe that patients can play an active and engaged role 
in research, becoming partners rather than participants. Our study 
methodology is collaboratively developed and patient-centered, 
an important consideration for patients and caregivers both in 
this lung cancer study and in other cancer studies.
To evaluate the first research question, we will utilize a cross-
sectional study in which we will simultaneously analyze infor-
mation on the outcome variable (patient-centered definition of  
treatment “success”) and its relationship to patient characteristics. 
We will deploy a prospective cohort study for the examination of  
the second research question because we will analyze changes in 
PCAE preferences over time, comparing multiple exposures (pa-
tient characteristics, real-life adverse effects experienced during 
chemotherapy, and drugs received for treatment). For the third 
research question, we will compare summary scores from a list 
of  adverse effects to a real-life drug choice. Both summary score 
and real-life drug choice information will be collected at the same 
point in time using a cross-sectional study design. For the fourth 
research question, we will determine whether a physician’s knowl-
edge of  a patient’s preferred PCAE affects the physician’s treat-
ment decisions. To answer this question, we will utilize a two-arm, 
physician-blinded, randomized, controlled design.
Study Population
Limited data are available on stage IV NSCLC patients in Nebras-
ka and South Dakota. We collected cross-sectional data from four 
participating cancer centers’ annual reports to justify our ability to 
enroll the required sample size and understand the basic demo-
graphics of  the study population. These background data clearly 
demonstrated the potential pool of  patients for recruitment and 
described the representativeness of  a sample.
Using prior year data, we estimated that 384 new patients would 
be seen at the four sites over a period of  two years. We calculated 
study power based on the expected final sample size available to 
test our hypotheses at specific time points of  interest, after ac-
counting for refusals, loss to follow-up, withdrawals, or other rea-
sons for not completing the study. Table1 demonstrates the rep-
resentativeness of  the lung cancer patients from the participating 
cancer centers to the states’ total number of  lung cancer patients 
for both Nebraska and South Dakota [12, 13, 14].
The average age of  lung cancer patients seen by the participating 
clinics was about 70 years. The average patient age at the cancer 
centers is similar to the national and state (Nebraska and South 
Dakota) averages (Figure1). Race and ethnicity of  treated patients 
in the four cancer centers mirrored that of  total populations for 
both Nebraska and South Dakota (Table1). About 50% of  di-
agnosed lung cancer patients reported rural residence, again re-
flecting the demographics of  the two states. Based on preliminary 
data, we expect that about 48% of  our patient population will be 
female and 52% male, which is consistent with national and state 
percentages of  lung cancer patients (Table 2) [15].
Existing data from the participating cancer centers showed the 
representativeness of  the population demographics of  the lung 
cancer patients in Nebraska and South Dakota. Our study sample 
represents age, gender, and race distribution similar to that of  the 
Figure 1: Study participants and visits, which is based on the preliminary data from the participating cancer centers.
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states’ total stage IV lung cancer patients.
Discussion
Although we expect higher participation and lower study proce-
dure-related attrition than is commonly seen in more invasive pro-
tocols, there will be a potential for missing and lost-to-follow-up 
data in our study over a three-year period. Based on the four can-
cer centers’ experiences with past clinical research, we do not an-
ticipate more than 5% missing data at baseline and no more than 
a 28% refusal rate (These factors are critical in sample size calcula-
tions.) Generalizability of  the study findings is another important 
aspect of  the clinical research. To maximize generalizability, we 
have carefully limited the exclusion criteria for this study. Patients 
who will not undergo chemotherapy will be excluded because our 
study research questions require that patients experience real-life 
treatment and treatment-related adverse effects. We excluded ad-
enocarcinoma patients because almost all of  these patients are 
treated with only one drug regimen (pemetrexed combination) 
due to its substantially lower toxicity profile and slightly higher 
efficacy compared to other options. Review of  the historical data 
from the participating cancer centers informed us about the avail-
Table1: Race/ethnicity distribution for the 2011 Nebraska (NE) population, 2000-09 NE lung cancer patients, 2006 South Dakota (SD) 
lung cancer patients and 2011 new stage IV lung cancer patients across the 4 study sites
Race and ethnicity Total population (NE, 2011)*
New lung cancer patients 
(NE, 2000-09)**
New lung cancer patients 
(SD,2006)***
New stage IV lung cancer patients 
(4 study sites, 2011) ¶
White 90.10% 94.70% 93.50% 93.00%
Black 4.70% 2.40% 0.00% 5.40%
American Indian, 
Alaska Native 1.30% 0.30% 5.70% 0.00%
Asian 1.90% 0.90% 0.00% 0.00%
Native Hawaiian 0.10%  --- 0.00% 0.50%
Mixed race  ---  --- 0.00% 1.10%
Hispanic 9.50% 0.90% 0.00% 0.00%
Total (n) 1,842,641 1,104 524 192
*Source: US Census Bureau (http://quickfacts. census.gov/qfd/states/31000.html)[10]. 
** Source: Nebraska HHS13 Data for 2010-11 to be released [11].
***Source: South Dakota Health Department. More recent data have not been released [12].
¶Source: study sites in Nebraska (UNMC, Callahan, St. Francis) and South Dakota (Avera)
Table 2. Gender distribution of  stage IV lung cancer patients at the 4 clinical sites (2011) [13]. 
Gender UNMC Avera St. Francis Callahan Total
Male 22 45 19 15  101 (52%)
Female 18 44 21 8 91 (48%)
Figure 2. Age at diagnosis of  lung cancer patients, Avera Cancer Institute site, 2001-2008 [Avera Cancer Institute, 2009]
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able lung cancer patient pool for study participation, estimating 
accurate samples, calculating statistical power, and providing con-
fidence on the generalizability of  the study findings. Moreover, 
data showed that we will have enough power for subgroup analy-
sis on gender, age, race, and residence status (rural/urban).
Choosing an appropriate design and relevant sample population 
for any epidemiological study is important for both internal and 
external validity. The study design allows us to translate the re-
search questions into operational questions. Adapting an inap-
propriate study design can raise a question of  internal validity; 
on the other hand, selecting inappropriate study participants can 
impact external validity. The study design that we selected could 
readily be applied to studying other cancers and chronic diseases 
in general. The uniqueness of  our stage IV lung cancer study is 
that there are a limited number of  chemotherapeutic treatments 
that have demonstrated differences in side effects. We did not 
investigate in any detail the treatment options for other cancers 
or chronic diseases such as diabetes or heart disease; however, 
the literature and our own experience suggest that patients would 
prefer being asked about their treatment preferences for many 
medical conditions. We anticipate that our study outcomes will 
provide useful information about patient-centered treatment for 
lung cancer and for other diagnoses.
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